|
| 9. |
ACCRUED
EXPENSES AND LONG-TERM LIABILITIES |
Other
accrued expenses consisted of the following as of June 30, 2021 and December 31, 2020:
SCHEDULE OF OTHER ACCRUED EXPENSES
| |
|
June 30, 2021 |
|
|
December 31, 2020 |
|
| |
|
(unaudited) |
|
|
|
|
| Accrued royalties |
|
$ |
3,320 |
|
|
$ |
2,710 |
|
| Upfront Medicare payment |
|
|
1,174 |
|
|
|
2,066 |
|
| Operating lease liability |
|
|
898 |
|
|
|
1,027 |
|
| All others |
|
|
897 |
|
|
|
1,182 |
|
| Accrued professional fees |
|
|
719 |
|
|
|
854 |
|
| Unclaimed property |
|
|
565 |
|
|
|
565 |
|
| Contingent consideration |
|
|
459 |
|
|
|
398 |
|
Accrued capital expenditures |
|
|
295 |
|
|
|
- |
|
Accrued pharma services invoices |
|
|
293 |
|
|
|
108 |
|
| Taxes payable |
|
|
289 |
|
|
|
334 |
|
| Accrued lab costs - diagnostics |
|
|
172 |
|
|
|
161 |
|
| Financing lease liability |
|
|
117 |
|
|
|
177 |
|
ESPP payable |
|
|
88 |
|
|
|
108 |
|
| Accrued sales and marketing - diagnostics |
|
|
78 |
|
|
|
51 |
|
| Deferred revenue |
|
|
43 |
|
|
|
54 |
|
| Total other accrued expenses |
|
$ |
9,407 |
|
|
$ |
9,795 |
|
Long-term
liabilities consisted of the following as of June 30, 2021 and December 31, 2020:
SCHEDULE OF LONG TERM LIABILITIES
| |
|
June 30, 2021 |
|
|
December 31, 2020 |
|
| |
|
|
(unaudited) |
|
|
|
|
|
| Uncertain tax positions |
|
$ |
4,454 |
|
|
$ |
4,342 |
|
| Warrant liability |
|
|
230 |
|
|
|
21 |
|
| Other |
|
|
92 |
|
|
|
138 |
|
| Deferred revenue |
|
|
25 |
|
|
|
136 |
|
| Total other long-term liabilities |
|
$ |
4,801 |
|
|
$ |
4,637 |
|
|